The upgrade from Market Perform to Outperform and the increased price target from $53 to $62 by Leerink Partners is likely to positively impact Ionis Pharmaceuticals' stock price in the short term. Analyst upgrades and higher price targets generally boost investor confidence and can lead to increased buying activity.